TLR agonists as adjuvants for cancer vaccines

Ji Kun Li; Jesse J. Balic; Liang Yu; Brendan Jenkins

doi:10.1007/978-981-10-5987-2_9

TLR agonists as adjuvants for cancer vaccines

Ji Kun Li, Jesse J. Balic, Liang Yu, Brendan Jenkins

Hudson Institute - Department of Molecular and Translational Science

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review

16 Citations (Scopus)

Abstract

Toll-like receptors (TLRs) are one of the best characterised families of pattern recognition receptors (PRRs) and play a critical role in the host defence to infection. Accumulating evidence indicates that TLRs also participate in maintaining tissue homeostasis by controlling inflammation and tissue repair, as well as promoting antitumour effects via activation and modulation of adaptive immune responses. TLR agonists have successfully been exploited to ameliorate the efficacy of various cancer therapies. In this chapter, we will discuss the rationales of using TLR agonists as adjuvants to cancer treatments and summarise the recent findings of preclinical and clinical studies of TLR agonist-based cancer therapies.

Original language	English
Title of host publication	Advances in Experimental Medicine and Biology
Editors	Irun R. Cohen, Abel Lajtha, John D. Lambris, Rodolfo Paoletti
Place of Publication	Gateway East Singapore
Publisher	Springer
Pages	195-212
Number of pages	18
Volume	1024
ISBN (Electronic)	978-981-10-5987-2
ISBN (Print)	978-981-10-5986-5
DOIs	https://doi.org/10.1007/978-981-10-5987-2_9
Publication status	Published - 2017

Publication series

Name	Advances in Experimental Medicine and Biology
Volume	1024
ISSN (Print)	0065-2598
ISSN (Electronic)	2214-8019

Keywords

Adjuvant
Agonist
Clinical trial
Toll-like receptor

Access to Document

10.1007/978-981-10-5987-2_9

241130059-oaAccepted author manuscript, 298 KB

Link to publication in Scopus

Cite this

@inbook{6982219b936f43c591b9a373c3958d27,

title = "TLR agonists as adjuvants for cancer vaccines",

abstract = "Toll-like receptors (TLRs) are one of the best characterised families of pattern recognition receptors (PRRs) and play a critical role in the host defence to infection. Accumulating evidence indicates that TLRs also participate in maintaining tissue homeostasis by controlling inflammation and tissue repair, as well as promoting antitumour effects via activation and modulation of adaptive immune responses. TLR agonists have successfully been exploited to ameliorate the efficacy of various cancer therapies. In this chapter, we will discuss the rationales of using TLR agonists as adjuvants to cancer treatments and summarise the recent findings of preclinical and clinical studies of TLR agonist-based cancer therapies.",

keywords = "Adjuvant, Agonist, Clinical trial, Toll-like receptor",

author = "Li, {Ji Kun} and Balic, {Jesse J.} and Liang Yu and Brendan Jenkins",

year = "2017",

doi = "10.1007/978-981-10-5987-2_9",

language = "English",

isbn = " 978-981-10-5986-5",

volume = "1024",

series = "Advances in Experimental Medicine and Biology",

publisher = "Springer",

pages = "195--212",

editor = "Cohen, {Irun R.} and Abel Lajtha and Lambris, {John D.} and Rodolfo Paoletti",

booktitle = "Advances in Experimental Medicine and Biology",

}

TLR agonists as adjuvants for cancer vaccines. / Li, Ji Kun; Balic, Jesse J.; Yu, Liang; Jenkins, Brendan.

Advances in Experimental Medicine and Biology. ed. / Irun R. Cohen; Abel Lajtha; John D. Lambris; Rodolfo Paoletti. Vol. 1024 Gateway East Singapore : Springer, 2017. p. 195-212 (Advances in Experimental Medicine and Biology; Vol. 1024).

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review

TY - CHAP

T1 - TLR agonists as adjuvants for cancer vaccines

AU - Li, Ji Kun

AU - Balic, Jesse J.

AU - Yu, Liang

AU - Jenkins, Brendan

PY - 2017

Y1 - 2017

N2 - Toll-like receptors (TLRs) are one of the best characterised families of pattern recognition receptors (PRRs) and play a critical role in the host defence to infection. Accumulating evidence indicates that TLRs also participate in maintaining tissue homeostasis by controlling inflammation and tissue repair, as well as promoting antitumour effects via activation and modulation of adaptive immune responses. TLR agonists have successfully been exploited to ameliorate the efficacy of various cancer therapies. In this chapter, we will discuss the rationales of using TLR agonists as adjuvants to cancer treatments and summarise the recent findings of preclinical and clinical studies of TLR agonist-based cancer therapies.

AB - Toll-like receptors (TLRs) are one of the best characterised families of pattern recognition receptors (PRRs) and play a critical role in the host defence to infection. Accumulating evidence indicates that TLRs also participate in maintaining tissue homeostasis by controlling inflammation and tissue repair, as well as promoting antitumour effects via activation and modulation of adaptive immune responses. TLR agonists have successfully been exploited to ameliorate the efficacy of various cancer therapies. In this chapter, we will discuss the rationales of using TLR agonists as adjuvants to cancer treatments and summarise the recent findings of preclinical and clinical studies of TLR agonist-based cancer therapies.

KW - Adjuvant

KW - Agonist

KW - Clinical trial

KW - Toll-like receptor

UR - http://www.scopus.com/inward/record.url?scp=85029668940&partnerID=8YFLogxK

U2 - 10.1007/978-981-10-5987-2_9

DO - 10.1007/978-981-10-5987-2_9

M3 - Chapter (Book)

C2 - 28921471

AN - SCOPUS:85029668940

SN - 978-981-10-5986-5

VL - 1024

T3 - Advances in Experimental Medicine and Biology

SP - 195

EP - 212

BT - Advances in Experimental Medicine and Biology

A2 - Cohen, Irun R.

A2 - Lajtha, Abel

A2 - Lambris, John D.

A2 - Paoletti, Rodolfo

PB - Springer

CY - Gateway East Singapore

ER -